纳武利尤单抗治疗复发或难治性儿童及年轻成人实体瘤或淋巴瘤:ADVL1412 多中心开放标签单臂1-2期试验
该多中心开放标签单臂1-2期试验评估纳武利尤单抗在复发或难治性非中枢神经系统实体瘤或淋巴瘤儿童及年轻成人中的安全性、药代动力学和抗肿瘤活性。85例患者入组,3 mg/kg 被确认为儿童推荐2期剂量,最常见毒性为贫血,淋巴瘤患者中观察到客观缓解,其他儿童常见实体瘤未见显著单药活性。
要点
- 纳武利尤单抗3 mg/kg在儿童及年轻成人中安全可耐受,被确认为儿童推荐2期剂量。
- 淋巴瘤患者观察到客观缓解,霍奇金淋巴瘤30%、非霍奇金淋巴瘤10%,所有缓解者均有PD-L1表达。
- 其他儿童常见实体瘤类型未观察到客观缓解。
核心结论
- 纳武利尤单抗在儿童及年轻成人中安全且耐受良好,在淋巴瘤中显示临床活性,但在常见儿童实体瘤中无显著单药活性。
研究设计与样本
- 多中心、开放标签、单臂、剂量确认与剂量扩展1-2期试验,在美国23家医院开展。
- A部分(剂量确认期)纳入1-18岁可测量或可评估疾病的实体瘤患者,不论组织学类型。
- B部分(剂量扩展期)纳入1-30岁可测量疾病的横纹肌肉瘤、尤文肉瘤、骨肉瘤、神经母细胞瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤和黑色素瘤患者。
- 2015年2月22日至2018年12月31日共入组85例患者,75例可完全评估毒性。
主要发现
- A部分13例入组、12例可评估毒性,无剂量递减或剂量限制性毒性,确认纳武利尤单抗3 mg/kg为儿童推荐2期剂量。
- B部分72例入组、63例可评估毒性,5例(7%)发生剂量限制性毒性。
- 总体最常见毒性为贫血(75例中35例[47%],其中5例为3级或4级),非血液学毒性最常见为乏力(28例[37%],无3级或4级)。
- 淋巴瘤患者观察到缓解:霍奇金淋巴瘤10例中3例(30%),非霍奇金淋巴瘤10例中1例(10%),所有缓解者均有PD-L1表达。
- 其他肿瘤类型未观察到客观缓解。
临床怎么用
- 本研究确定的儿童推荐2期剂量为纳武利尤单抗3 mg/kg静脉输注,可作为儿童癌症联合方案研究的依据。
- 在复发或难治性儿童常见实体瘤中,不推荐纳武利尤单抗单药治疗。
- 淋巴瘤患者可考虑进一步研究纳武利尤单抗,尤其是PD-L1表达者。
局限性
- 单臂设计,无对照组。
- 中位随访仅30天(IQR 27-83),随访时间较短。
- 部分患者未完全可评估毒性(85例中75例可评估毒性)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors targeting PD-1 have shown clinical benefit in adults with cancer, but data on these drugs in children are scarce. We did a phase 1-2 study of nivolumab, a PD-1 blocking monoclonal antibody, to determine its safety, pharmacokinetics, and antitumour activity in children and young adults with recurrent or refractory non-CNS solid tumours or lymphoma. METHODS: We did a multicentre, open-label, single-arm, dose-confirmation and dose-expansion, phase 1-2 trial in 23 hospitals in the USA. Eligible patients for part A (dose-confirmation phase) of the study were aged 1-18 years with solid tumours with measurable or evaluable disease (by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) regardless of histology. Eligible patients for part B (dose-expansion phase) were aged 1-30 years with measurable disease (by RECIST criteria) in the following disease cohorts: rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, neuroblastoma, Hodgkin lymphoma, non-Hodgkin lymphoma, and melanoma. Patients in part A and were given nivolumab 3 mg/kg intravenously over 60 min on days 1 and 15 of a 28-day cycle in a rolling 6 study design with de-escalation upon dose-limiting toxicities to establish the recommended phase 2 dose. Patients in part B were given the recommended phase 2 dose. The primary outcomes were the tolerability, systemic exposure, maximum tolerated dose, and the antitumour activity of nivolumab at the adult recommended dose in children and young adults. This trial is registered with ClinicalTrials.gov, NCT02304458, with follow-up ongoing and is closed to new participants. FINDINGS: 85 patients were enrolled between Feb 22, 2015, and Dec 31, 2018, and 75 patients were fully evaluable for toxicity. Median follow-up was 30 days (IQR 27-83). In part A, 13 patients were enrolled and 12 were evaluable for toxicity. There were no dose de-escalations or dose-limiting toxicities and nivolumab 3 mg/kg was confirmed as the paediatric recommended phase 2. 72 patients were enrolled in part B and 63 were evaluable for toxicity. Five (7%) patients in part B had dose-limiting toxicities. The most common overall toxicity was anaemia (35 [47%] of 75 patients; five patients had grade 3 or grade 4) and non-haematological toxicity was fatigue (28 [37%] patients; none had grade 3 or grade 4). Responses were observed in patients with lymphoma (three [30%] of ten with Hodgkin lymphoma and one [10%] of ten with non-Hodgkin lymphoma; all responders had PD-L1 expression). Objective responses were not observed in other tumour types. INTERPRETATION: Nivolumab was safe and well tolerated in children and young adults and showed clinical activity in lymphoma. Nivolumab showed no significant single-agent activity in the common paediatric solid tumours. This study defines the recommended phase 2 dose and establishes a favourable safety profile for nivolumab in children and young adults, which can serve as the basis for its potential study in combinatorial regimens for childhood cancer. FUNDING: Bristol-Myers Squibb, Children's Oncology Group, National Institutes of Health, Cookies for Kids Cancer Foundation.
引用
- Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020. PMID: 32192573. doi:10.1016/S1470-2045(20)30023-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。